Aberrant status and clinicopathologic characteristic associations of 11 target genes in 1,321 Chinese patients with lung adenocarcinoma
Aberrant status and clinicopathologic characteristic associations of 11 target genes in 1,321 Chinese patients with lung adenocarcinoma
复制标题
1,321例中国肺腺癌患者11个靶基因的异常状态和临床病理特征关联
DOI：
10.21037/jtd.2017.12.68
复制
发表时间：
2018-01-01
影响因子：
2.5
通讯作者：
Wang, Qun
中科院分区：
文献类型：
--
作者：
Zhao, Mengnan;Zhan, Cheng;Wang, Qun
背景：在原发性肺腺癌中，靶基因的异常状态及其与临床病理特征的关联仍不清楚。
方法：对1247例手术切除的原发性肺腺癌标本中9个靶基因的常见突变和易位进行评估。采用免疫组织化学方法分析731例标本中程序性死亡受体1（PD - 1）/程序性死亡配体1（PD - L1）的表达。分析基因异常的频率及其与临床病理特征的关联。
结果：在1247例患者中，共有952例（76.3%）至少存在一种靶基因突变或易位：表皮生长因子受体（EGFR）（729例，58.5%）、v - Ki - ras2 Kirsten大鼠肉瘤病毒癌基因同源物（KRAS）（83例，6.7%）、人表皮生长因子受体2（HER2）（82例，6.6%）、间变性淋巴瘤激酶（ALK）（23例，1.8%）、磷脂酰肌醇 - 3 - 激酶催化α亚基（PIK3CA）（20例，1.6%）、Ret原癌基因RET（15例，1.2%）、ROS原癌基因1受体酪氨酸激酶（ROS1）（12例，1.0%）、B - raf原癌基因（BRAF）（9例，0.7%）、神经母细胞瘤RAS病毒（v - ras）癌基因同源物（NRAS）（3例，0.2%）。731例患者中有14例（1.9%）PD - 1阳性，95例（13.0%）肿瘤细胞中PD - L1阳性。在男性和吸烟者中，KRAS突变更为频繁（两者均P……（此处原文似乎不完整）
Background: The aberrant status of target genes and their associations with clinicopathologic characteristics are still unclear in primary lung adenocarcinoma.Methods: The common mutations and translocations of nine target genes were evaluated in 1,247 specimens of surgically-resected primary lung adenocarcinoma. Immunohistochemistry was used to analyze the expressions of programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) in 731 specimens. The frequency of the aberrations and their associations with clinicopathologic characteristics were analyzed.Results: Overall, 952 (76.3%) of 1,247 patients harbored at least one target mutation or translocation: epidermal growth factor receptor (EGFR) (729, 58.5%), v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) (83, 6.7%), human epidermal growth factor receptor 2 (HER2) (82, 6.6%), anaplastic lymphoma kinase (ALK) (23, 1.8%), phosphoinositide-3-kinase catalytic alpha polypeptide (PIK3CA) (20, 1.6%), Ret proto-oncogene RET (15, 1.2%), ROS proto-oncogene 1 receptor tyrosine kinase (ROS1) (12, 1.0%), B-raf proto-oncogene (BRAF) (9, 0.7%), neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS) (3, 0.2%). Fourteen (1.9%) of 731 patients were PD-1 positive and 95 (13.0%) were PD-L1 positive in tumor cells. In men and smokers, there were more frequent KRAS mutations (both P